Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
CSL acquired Vifor Pharma for $11.7B for iron deficiency, kidney, and cardio-renal diseases.
CSL CEO cited dampened near-term financial growth expectations for CSL Vifor due to CMS reimbursement bundling, generic Venofer competition, and lackluster…
CSL Vifor floated a 23M GBP settlement with UK Competition and Markets Authority over allegations it furnished doctors with misleading information about rival…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
CSL acquired Vifor Pharma for $11.7B in an all-cash tender offer ($179.25/share, 61% premium; closed 9 Aug 2022) to diversify beyond plasma into iron-deficiency, nephrology and cardio-renal disease. Post-close the thesis has deteriorated: at its 1H FY26 results (period ended 31 Dec 2025) CSL booked US$843M after-tax impairments on CSL Vifor and CSL Seqirus intangibles, with the Vifor portion largely tied to VENOFER after lower sales forecasts driven by generic competition. On 11 May 2026 interim CEO Gordon Naylor flagged a further ~US$5B in non-cash pre-tax impairments across FY26-FY27 (on top of US$1.5B at 1H FY26), explicitly including CSL Vifor intangibles and under-utilised property, plant and equipment, and cut FY26 guidance to ~US$15.2B revenue and ~US$3.1B NPATA. The write-downs represent CSL effectively conceding the Vifor deal has not delivered its original returns.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| CSL Limited / Vifor Pharma Group (this deal) | 2021 | $11.7B | 58 |
| CSL Limited / Memo Therapeutics AG | 2026 | $328M | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance | 2012 | $3.5B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Metabolic deals